Patent details
300475
Product Name:
Combinatie van meningokokkaal groep A oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit, meningokokkaal groep C oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit, meningokokkaal groep W135 oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit en meningokokkaal groep Y oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit.
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300475
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1741442
Status:
Expired Art. 14 (a) of the EC Regulations
Application number:
300475
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)
Marketing Authorization
Marketing Authorization Number:
EU/1/10/614/001
Marketing Authorization Type:
EEA
Marketing Authorization Date:
17/03/2010
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
14/01/2011
First Marketing Authorization date:
17/03/2010
Grant date:
23/03/2011
Activation date:
20/06/2022
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
14/01/2011
SPC/SPC Extension Expiration Date:
16/03/2025
Lapsed By Expiration Date:
17/03/2025
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
22/12/2021
Name:
GlaxoSmithKline Biologicals S.A.
Address:
Rue de l'Institut 89, 1330, Rixensart, Belgium (BE)
Historical Applicant/holder
From:
14/01/2011
To:
22/12/2021
Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)
Agent
Name:
ir. F.A. Geurts c.s.
From:
21/02/2018
Address:
Octrooibureau Vriesendorp & Gaade B.V.
Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
12/25
Publication date:
19/03/2025
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
25/22
Publication date:
22/06/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
3
Bulletin Heading:
CO
Journal edition number:
05/22
Publication date:
02/02/2022
Description:
Changes in the Netherlands Patent Register
4
Bulletin Heading:
SPC
Journal edition number:
2011/13
Publication date:
30/03/2011
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
5
Bulletin Heading:
SPC
Journal edition number:
2011/04
Publication date:
26/01/2011
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Deed
Change of owner(s)
Change Kind/ Decision Type:
Assignment
Deed Number:
RC202102715A
Date Registered:
22/12/2021
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. F.A. Geurts c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Added Owner(s)
Name:
GlaxoSmithKline Biologicals S.A.
Address:
Rue de l'Institut 89, 1330, Rixensart, Belgium (BE)
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Annual Fee
Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
21/05/2024
Last Annual Fee Paid Number:
23
Last Annual Fee Paid Amount:
2000 Euro
Payer:
Anaqua Services
Filing date
Document type
Document Description
Number of pages
File Type
14/12/2018
SPC Documents
Accompanying letter SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_12_supplprotectioncertificate20200908112108808.pdf
05/01/2016
SPC Documents
Certificate SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_4_supplprotectioncertificate20200908111737374.pdf
05/01/2016
Outgoing Correspondence
Decision grant
1
PDF
/5/7/4/0/0/0400300475/docs/300475_6_outgoingcorrespondence20200908111435231.pdf
27/11/2015
SPC Documents
Accompanying letter SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_1_supplprotectioncertificate20200908104911246.pdf
27/11/2015
SPC Documents
Annex SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_10_supplprotectioncertificate20200908110158537.pdf
11/05/2011
SPC Documents
Certificate SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_5_supplprotectioncertificate20200908104106918.pdf
11/05/2011
Outgoing Correspondence
Outgoing Letter
1
PDF
/5/7/4/0/0/0400300475/docs/300475_13_outgoingcorrespondence20110323.pdf
05/05/2011
SPC Documents
Accompanying letter SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_0_supplprotectioncertificate20200908103342020.pdf
23/03/2011
Outgoing Correspondence
Outgoing Letter
1
PDF
/5/7/4/0/0/0400300475/docs/300475_7_outgoingcorrespondence20110323.pdf
23/03/2011
SPC Documents
Certificate SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_8_supplprotectioncertificate20200908102906746.pdf
18/01/2011
Outgoing Correspondence
Outgoing Letter
1
PDF
/5/7/4/0/0/0400300475/docs/300475_14_outgoingcorrespondence20110118.pdf
14/01/2011
Application Form
First filed application form
3
PDF
/5/7/4/0/0/0400300475/docs/300475_2_applicationform20110114.pdf
14/01/2011
SPC Documents
Accompanying letter SPC
1
PDF
/5/7/4/0/0/0400300475/docs/300475_3_supplprotectioncertificate20200908101724592.pdf
14/01/2011
SPC Documents
Marketing Authorization SPC
3
PDF
/5/7/4/0/0/0400300475/docs/300475_9_supplprotectioncertificate20200908093306620.pdf
14/01/2011
SPC Documents
Summary of the characteristics of the product
11
PDF
/5/7/4/0/0/0400300475/docs/300475_11_supplprotectioncertificate20200908094150863.pdf